Exagamglogene Autotemcel for Severe Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A . Methods We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening. CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months. A key secondary end point was freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months. The safety of exa-cel was also assessed. Results A total of 44 patients received exa-cel, and the median follow-up was 19.3 months (range, 0.8 to 48.1). Neutrophils and platelets engrafted in each patient. Of the 30 patients who had sufficient follow-up to be evaluated, 29 (97%; 95% confidence interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months, and all 30 (100%; 95% CI, 88 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months (P<0.001 for both comparisons against the null hypothesis of a 50% response). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No cancers occurred. Conclusions Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Self-citationGluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Pinto Simões, B., Ferster, A., Dupont, S., de la Fuente, J., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745711 · Cited by 495
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationA trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy, S., Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-715870 · Cited by 216
Self-citation
Cited by
Items 301–400 of 477
CRISPR: fundamental principles and implications for anaesthesia
Perez, A. R., Mavrothalassitis, O., Chen, J. S., Hellman, J., & Gropper, M. A. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.11.040 · Cited by 1
“106,127 The adverse events most common and germane to anaesthesia care were stomatitis (55% and 40%, respectively), febrile neutropenia (48% and 54%, respectively), and thrombocytopenia (25% and 35%, respectively), with their resultant implications for pain control, antibiotic management, and…”
Two is better than one: Advancing gene therapy protocols for enhanced safety and efficacy
Hardouin, G., & Miccio, A. (2025) · Cell stem cell · doi:10.1016/j.stem.2024.12.009
Cures for Sickle Cell Abound — How about Access?
Hong, S., & Horwitz, M. E. (2025) · NEJM Evidence · doi:10.1056/evide2400428
Introducing the Gene & Cell Therapy Study Group of the ASNR, ASFNR, and ASPNR
Narsinh, K. H., Grant, P. E., Barajas, R., Ivanidze, J., Shah, B., Pukenas, B. A., Tanabe, J., Hess, C. P., & Lindan, C. E. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8745
Clinical applications of gene editing and therapy
Badat, M., & Davies, J. O. J. (2025) · Wiley eBooks · doi:10.1002/9781119706687.ch7
Slabaugh, B., & Anderson, E. E. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2025.2470671
Nakagawa, A., Morwood, K., Johnson, K., Berra, L. M., Boal, L. H., Azar, S., Huang, M., Heeney, M. M., Bloch, D. B., & Ichinose, F. (2025) · ACS Omega · doi:10.1021/acsomega.4c11077 · Cited by 1
A Brief History of Pediatrics and the Beginnings of Pediatric Engineering
Phoon, C. K. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-84655-7_1
What's Best? Transformative Therapies for Adults with Sickle Cell Disease
Strouse, J. J., & Kassim, A. A. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.04.004
Killer, M. C., Zhang, X., Adhikary, T., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6470951/v1
CRISPR/Cas gene editing of haematopoietic stem cells for curing primary immunodeficiency
Bak, R. O., Holm, M., Møller, B. K., Mikkelsen, J. G., & Mogensen, T. H. (2025) · Ugeskrift for Læger · doi:10.61409/v02250083
CRISPR as a functional cure for hemoglobinopathies
Glenthøj, A. B., Carlsen, S. B. I. S., Hoffmann, M. H., Haastrup, E. K., Andersen, L. P., Toft, N., Kornblit, B. T., Petersen, J., Hasle, H., & Ifversen, M. (2025) · Ugeskrift for Læger · doi:10.61409/v12240888
Clinical consultation: The pharmacist’s role in hydroxyurea management for sickle cell disease
Roessner, C., Uminski, K., Goodyear, D. M., & Rydz, N. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf114
Zanders, E. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-93949-5_6 · Cited by 1
Gene Therapy & Gene-Editing Techniques
LaRocca, C. J., & Steer, C. J. (2025) · Success in academic surgery · doi:10.1007/978-3-031-83034-1_13
Pecker, L. H. (2025) · doi:10.1182/ashsap9.chapter11
Balusu, R., Soder, R. P., Dudley, N. R., McGuirk, J. P., & Abhyankar, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.027
Srinivas, M., Jaspersen, S. L., Wilson, D. B., & Hulbert, M. L. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31937
Chao, G., Appleton, E., Gutierrez, C. S., Evgeniou, L., Daifuku, T., Wannier, T. M., Mintzer, E., & Church, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.668540 · Cited by 1
Cardiovascular disease in Sickle cell: mechanisms, diagnostics and therapeutic advances
Haroun, E., Agrawal, A., Arockiam, A. D., Dahdah, J. E., Kassab, J. T., Nakhla, M., Helou, M. C. E., Sanaka, H., Zalaquett, Z., Kaur, S., et al. (2025) · Heart · doi:10.1136/heartjnl-2025-325837 · Cited by 2
Ethical and Legal Dimensions of Access to CRISPR Technologies in Rare Disease Therapies
Telli, K., Özdemir, B., Danışman, S., & Yücesan, E. (2025) · Genetics. · doi:10.5772/intechopen.1012213
Sickle cell disease and the kidney
Sharpe, C. C. (2020) · doi:10.1093/med/9780198746690.003.0497_update_001
Limerick, E. M., Hsieh, M. M., Queen, J., et al. (2025) · medRxiv · doi:10.1101/2025.08.31.25334807
“Autologous gene therapy and gene editing strategies are being developed; the Food and Drug Administration recently approved two approaches [20, 21].”
Life-long hydroxyurea treatment decreases chronic pain in sickle cell disease micePreprint
Gayluak, N., Roy, S., Plumb, A. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.30.673263
CURRENT STATUS AND PROSPECTS OF GENOME EDITING TECHNOLOGIES
Lesniak, Y. I., Кулібаба, Р. О., Kopylov, K., Kopylova, K., & Kulibaba, S. V. (2025) · Animal Breeding and Genetics · doi:10.31073/abg.70.11
Reality bites: allocating gene therapy for hemoglobinopathies
Tubman, V. N., & Fasipe, T. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016943
A novel ANK1 frameshift mutation associated with neonatal hereditary spherocytosis: a case report
Qing, X., Zhu, J., Zhu, X., et al. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1666585
Cutting Through the Artifacts: Dissecting gRNA Impurities with FUSS-seqPreprint
Montalbano, A., Qiu, H., Karthik, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.13.676056
Gene Therapy for Sickle Cell Disease: No Donor, No Problem
Smilow, E. (2025) · Clinical journal of oncology nursing · doi:10.1188/25.cjon.371-375
Thalassämie und Sichelzellanämie: Probate Therapien bestätigt, innovative Verfahren in der Prüfung
Eckert, N., & Frimmer, V. (2025) · Deutsches Ärzteblatt · doi:10.3238/perspaed.2025.10.03.07
Wang, T., Jessa, S., Marinov, G. K., Klemm, S. L., Kundaje, A. B., & Greenleaf, W. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.25.678665
Enhancing Biotechnological Applications Using an Optimized Semiconductor Refrigeration Device
Zhang, G., Li, Y., Pang, H., Tu, Q., & Wang, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c11150
Cyp7b1-inhibiting azoles as novel enhancers of hematopoietic stem and progenitor cell mobilizationPreprint
Vu, B. L., Roeder, T. J., Kanaujiya, J. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.13.682145
CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectives
Zingarelli, F., Nanni, J., Cristiano, G., Zannoni, L., & Curti, A. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102582
Sustained expression of hemopexin in an animal model of sickle cell anemia
de Lima, F., Moraes, C. R. P., Borba-Junior, I. T., Assalin, H. B., Saad, M. J. A., Costa, F. F., & Paula, E. V. D. (2025) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2025.100115 · Cited by 1
Engineering Cancer with Next-Generation Genome Editing Tools
Roth, J. F., Chen, E., Cevasco, H., & Rivera, F. J. S. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070824-123431
How far have we come? From understanding collagen disorders to advancing treatment strategies
Williamson, J., Chong, Y. Y., Hung, W. K., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00572-3
Charlotte, E. E., Edgar, M. M. L., Betoko, M. R., Iyawa, H., Ngenge, M. B., & Christiane, K. K. D. (2025) · Open Journal of Blood Diseases · doi:10.4236/ojbd.2025.154013 · Cited by 1
El-Khalifa, B. M., Soliman, W. A., Mazy, H. M., Ahmed, M. G., Al-Trad, H., Elmeneizee, T. H., El-Aziz, H. W. A., Abdelmutaleb, S. A. H., Abdelghaffar, G. A., & Morsi, M. H. (2025) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-025-00806-4 · Cited by 4
Reproductive Considerations of Gene Therapies for Sickle Cell Disease and Beta-Thalassemia
Sorouri, K., Cliff, E. R. S., Glass, K., & Michaeli, J. (2025) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2025.103179
Demystifying Gene-Based Therapies in Pediatric Health Care
Tinkle, M. B., & Schluter, W. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2025.105611
Optimizing the “right” patient selection for treatment for sickle cell disease
Colombatti, R., & Reggiani, G. (2025) · Hematology · doi:10.1182/hematology.2025000751
Gao, Z., Lin, K., Gong, Y., Zhao, Y., & Zhang, S. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c02069
Sickle cell disease and thalassemia go to the PROm
Abboud, M. R., & Andemariam, B. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017436
Disrupting epigenetic insulation underlies CRISPR therapy for β-hemoglobinopathies
Wang, K., Wang, J., Weiss, M. J., Yue, F., & Xu, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.015
Biard, L., Lévy, V., Chevret, S., Künkele, A., Grunwald, S., Aiuti, A., Møller, B. K., Debets, R., Mielke, S., Eldere, J. V., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201651 · Cited by 1
CRISPR-Based Gene Therapy: Implications for the Clinical Laboratory
Bradbury, A. M., Kozel, B. A., & Mardis, E. R. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf100
Edición Genética de las Células Madre con CRISPR-Cas: Avances en la Medicina Regenerativa
Sánchez, G. P. V., Villacís, I. S., & Ocaña, T. V. (2025) · Revista Científica Multidisciplinar G-nerando · doi:10.60100/rcmg.v6i2.894
Transcription factor binding to the γ-globin promoter regulates the γ-to-β-globin switch
Wei, X.-R., Huang, X.-H., Liu, S.-E., Zhao, Y.-J., Chen, M., Jin, D., Gao, Y., Zhang, Y.-H., Ai, H.-X., Ma, Y.-L., et al. (2026) · Reproductive and Developmental Medicine · doi:10.1097/rd9.0000000000000151
Iterative engineering of a compact Cas9 ortholog for in vivo gene editing via single AAV deliveryPreprint
Barenghi, A., Hackett, J. A., Humphreys, N. E., & Sawitzke, J. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.698990
Modern therapeutic approaches for β-thalassemia: from blood transfusion to gene therapy
Dolgushina, E. N., Коптева, О. С., Shakirova, A. L., Lepik, K. V., Bykova, T. A., Zubarovskaya, L. S., & Kulagin, A. (2026) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2025-12-3-56-67
Gene-Editing-Based Approaches for Curing Sickle Cell Disease
Park, S. H., Karsenty, C. L., Prasca-Chamorro, D., Moyo, B., Yoo, B., & Bao, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_8 · Cited by 1
Therapeutic Genome Engineering for the Treatment of Sickle Cell Disease
Leonard, A. K., Sharma, A., Chao, F.-Y., & Yen, J. S. (2026) · Springer eBooks · doi:10.1007/978-3-032-12532-3_9 · Cited by 1
Self-citationGlobal research landscape of inborn errors of immunity: a bibliometric analysis (1991–2025)
Wu, Q., Gao, J., Yuan, Y., Yang, H., & Fu, Q. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04191-4 · Cited by 1
Zaidi, S. Z. H., Vasudev, M. M., & Mavathur, R. N. (2026) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2026.100152
Frangoul, H., McManus, M. P., Carroll, C., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.12.037
Self-citationLDB1 represses fetal hemoglobin expression by enhancing BCL11A transcription
Park, S.-W., Choi, C., Park, I.-B., Kang, S. J., Lee, H. J., Kim, J.-I., Bae, J., Geum, D., Cheon, Y. P., & Chun, T. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104070
Synergistic integration of inducible RNA switches enhances the manipulation of vector expressionPreprint
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Lu, T., Zhang, Y., Zhao, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704328
Novel therapeutics in autism spectrum disorder
Kevelson, S. D., Elmaghraby, R., Patel, F., Brown, H. R., Gorenstein, M., Bain, J., Grinspan, Z. M., Pedapati, E. V., Veenstra-VanderWeele, J. M., & Vandana, P. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00857 · Cited by 7
“Phase 3 trials demonstrated substantial reductions in vaso-occlusive crises for people with sickle cell disease [207] and transfusion dependence in people with beta-thalassemia [208].”
AlMoshary, M., Qushmaq, N. A., Elgujja, A. A., Alamoudi, A., Alqahtani, M. S., Bugshan, H. S., Antony, M., & Alshahrani, F. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s556083
Lin, J., Dong, W., Zhang, J., Xie, C., Jing, X., Zhao, J., Ma, K., Kang, H., Jiang, Y., Xie, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.03.708783
Shin, E. J., Choi, Y., Jeon, E. J., Lee, K.-I., Lee, K.-J., Son, Y. J., Son, M. J., Kim, S., Cho, S., & Lee, J. Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.005 · Cited by 1
Zero-net mass-flux jet microfluidic delivery platform for multitype cell transfection
Xu, H., Mao, Z., Liu, P., Gao, X., Zhang, M., Ekaterina, V., Hu, G., & Wu, J. (2026) · Physics of Fluids · doi:10.1063/5.0314516
Delemarre, L., Huys, I., Dyck, W. V., & Simoens, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1749386 · Cited by 1
Genetic influences on haematopoiesis
Poeschla, M., & Sankaran, V. G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00947-1 · Cited by 3
Targeting enhancer RNAs to silence transcription
Perkins, A. C. (2026) · Blood · doi:10.1182/blood.2025032076
Mannstadt, M., & Wein, M. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00041-4
Ye, T., Xu, W., Barrachina, M. N., Lyu, P., Antoszewski, M., della Volpe, L., Guo, C., Lee, A., Villalpando, E., Johnson, I. A., et al. (2026) · Cell stem cell · doi:10.64898/2026.03.27.714536
Transcriptional Regulatory Modulation as a Potential Therapeutic Modality
Matharu, N. K., & Ahituv, N. (2026) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120324-124041
Genome and epigenome editing approaches to treat β-hemoglobinopathies
Fontana, L. (2024) · theses.fr (ABES) · doi:10.70675/f1623d8bz5529z4d2dzb255z45ed273f643c
Cohrt, K. O., & O’Dea, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083384
“Patients exhibited early and sustained increases in total hemoglobin and HbF levels, and improvements were seen in all markers of hemolysis evaluated [72].”
Kuo, C. Y., Harrington, S., Campo-Fernández, B., Wyman, S. K., Wu, X., Zhang, R., Espinoza, A., Silva, B. J. D. A., Sanchez, J. M., Fitz‐Gibbon, S. T., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05010-8
Gene Editing for Haemophilia—The Next Frontier
Pinotti, M., Newby, G. A., Selvaraj, S. R., & Pipe, S. W. (2026) · Haemophilia · doi:10.1111/hae.70238 · Cited by 1
Immune Effector Cell and Gene Therapies in Pediatric Critical Care
Ragoonanan, D. S., & Mahadeo, K. M. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_200-2
Singh, S., Shahadab, M., Sachin, K., Pandey, R. K., Trivedi, P., Mishra, A. K., & Jha, H. C. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10228-1
Foord, E., Sairafi, D., Berg, M., Westerling, S., Adigun, T., Uzunel, M., Papasavva, T., & Uhlin, M. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1810737 · Cited by 2
Novel phosphatase-based regulatory loop for HbF expression
Franceschi, L. D. (2026) · Blood · doi:10.1182/blood.2025032772
Khare, G., Duong, A., Hanotaux, J., Shorr, R., Nampoothiri, R. V., Maganti, H. B., & Allan, D. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102898 · Cited by 1
Benmhammed, H., Sun, Y., Abdullatif, S. A., Chen, A., Khan, S., Zadeh, A. M., Mazile, N., Beacham, G. M., Mahdaviani, K., Williams, C., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018409
Self-citationArji, S., Shen, Z., Welch, S., ElMahdaoui, F., Bahadur, A., Lee, E., Lee, H., Wu, S.-C. P., Konshina, E., Ayubali, B., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00911-5 · Cited by 1
Hematopoietic Stem Cell-Based Cell and Gene Therapy Beyond Monogenic Diseases
Kai, M., & Mavilio, F. (2026) · Stem Cells and Development · doi:10.1177/15473287261444631
The paradox of HbSC disease—Not so benign after all
Lyde, R. B., & Novelli, E. M. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.05.001 · Cited by 1
Perspective Chapter: Novel Therapeutics in SCD-Fetal Hemoglobin Inducers
Jena, R. K., Nayak, A. R., & Sethy, S. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015656
Histoire de l’hématologie pédiatrique
Sirvent, N. (2026) · Perfectionnement en Pédiatrie · doi:10.1016/j.perped.2026.04.005
Design of Chimeric Antigen Receptor (CAR) T Cell Therapy
Tristán‐Manzano, M., de Franscisco, J. R., Hinckley-Boned, A., & Martín, F. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_38
Angiogenic Doping: Plausible Yet Difficult to Detect
Lehto, S., Sima, S., Künnapuu, J., Iljukov, S., & Jeltsch, M. (2026) · Sports Medicine · doi:10.1007/s40279-026-02447-y
Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies
Blandy, O., Lembo, P., Folorunso, R., et al. (2026) · Journal of Market Access & Health Policy · doi:10.3390/jmahp14020032
“…data on the effectiveness and safety of an OMP in patients with uncommon disease types or other characteristics that would make them under-represented in RCTs conducted in an already rare disease (e.g., patients with a non-HbSS genotype in trials of gene therapies in sickle cell disease [36,37]).”
The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Tardif, M., Saby, M., Forté, S., & Pincez, T. (2026) · Cells · doi:10.3390/cells15100939
“Long-term follow-up data beyond 5 years are available for only a minority of treated patients, and the durability of gene correction over a patient’s lifetime has not been established [62,73].”
Hematopoietic Cell Transplantation for Sickle Cell Disease
Guilcher, G. M. T. (2026) · Children · doi:10.3390/children13060741
CRISPR and Fanzor in sickle cell disease: current progress and future prospects
Humoudi, A. Y. A., Alotaibi, A. G., Alosaimi, N. F., Alshalani, A., Alqahtani, S. D., Alsaab, S. M., Almutiri, B. J., & Albariqi, M. M. H. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1774014
Pain in SCD—Many mechanisms and mysteries
Martin, O. Y., & Darbari, D. S. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.05.006 · Cited by 1
HbF/F-cell and the Phenotype of Sickle Cell DiseasePreprint
Lofters, J., Wilks, A., Lee, J. W., Hicks, J. M., Klings, E. S., & Steinberg, M. H. (2026) · medRxiv · doi:10.64898/2026.06.02.26354737
Self-citationAn, J., Bai, J., Li, L., Xinsai, L., Zhang, Y., & Lv, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08389-3 · Cited by 1
CRISPR application in hematological disorders: from bench to bedside
Ladisa, F., Morelli, E., Soncini, D., Garibotto, M., Munshi, N. C., Fulciniti, M., & Cea, M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017417 · Cited by 1
Genome editing in Africa: A review of technological advances, applications, and the path forward
Johnson, A. M., Isiaka, I. D., Merenini, I. F., Iyanuoluwa, O. V., Violet, M. S., & Abubakari, A. W. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03445 · Cited by 1
Charting the computational landscape of single-cell genetic perturbation
Zhang, Y., Huang, J., Li, Y., Liu, T., Ren, L., Huang, J. H., Lin, H., Feng, J., & Zhang, Y. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.06.012 · Cited by 1
Rastogi, D., Gabbay, J. M., Beck, A. F., Ghazala, Z., Willen, S. M., Cohen, R. T., Rosas‐Salazar, C., Cabana, M. D., & Teach, S. J. (2026) · PEDIATRICS · doi:10.1542/peds.2026-076070d · Cited by 1
Cardiac immunity and heart repair: Mechanism, challenge, and future direction
Liu, Y., Ren, Q., Wang, H. T., Jiang, X., Zhao, M. H., Min, Q., Xie, Y., Cai, D., & Nie, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004078 · Cited by 1
“[378] The integration of lineage tracing with fluorescent reporters, single-cell omics, and genome editing will offer unprecedented insight into developmental and disease processes.”
Minaiyan, G., Aussel, C., Ammann, S., & Cathomen, T. (2026) · Human Gene Therapy · doi:10.1177/10430342261465555
Sharma, A., & Corbacioglu, S. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019856
Self-citation
Metadata
- Authors
- Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., Cavazzana, M., Corbacioglu, S., Rondelli, D., Meisel, R., Dedeken, L., Lobitz, S., de Montalembert, M., Steinberg, M. H., Walters, M. C., Eckrich, M. J., Imren, S., Bower, L., Simard, C., Zhou, W., Xuan, F., Morrow, P. K., Hobbs, W. E., & Grupp, S. A.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; IRCCS, Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome (F.L.); the Department of Pediatrics, Columbia University Irving Medical Center, New York–Presbyterian–Morgan Stanley Children’s Hospital (M.B.), and the Department of Medicine, Division of Hematology–Oncology, Columbia University (M. Mapara) — both in New York; Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital, San Antonio, TX (L.M., M.J.E.); the Hospital for Sick Children and the University of Toronto, Toronto (D.W.); Ann and Robert H. Lurie Children’s Hospital of Chicago (R.I.L.) and the University of Illinois at Chicago (D.R.) — both in Chicago; Royal London Hospital, Barts Health NHS Trust, London (P.T.); Stanford University, Palo Alto (A.J....
- ORCID
- Frangoul, Haydar
- Locatelli, Franco
- Sharma, Akshay
- Bhatia, Monica
- Mapara, Markus
- Wall, Donna
- Liem, Robert I.
- Telfer, Paul
- Shah, Ami J.
- Cavazzana, Marina
- Corbacioglu, Selim
- Rondelli, Damiano
- Meisel, Roland
- Dedeken, Laurence
- Lobitz, Stephan
- Steinberg, Martin H.
- Walters, Mark C.
- Eckrich, Michael J.
- Imren, Suzan
- Zhou, Weiyu
- Xuan, Fengjuan
- Morrow, Phuong Khanh
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1649-1662
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068280
- Cited by
- 493
- References
- 29
- Citations by year
- 2026: 217 · 2025: 201 · 2024: 74
- FWCI
- 137.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vertex Pharmaceuticals
- CRISPR Therapeutics
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, sickle cell disease, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin reactivation, hematopoietic stem and progenitor cells, vaso-occlusive crisis, myeloablative conditioning, busulfan, autologous cell transplantation, cell therapy safety, pediatric patients
- MeSH terms
- Gene Editing, Adolescent, Adult, Anemia, Sickle Cell, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.